» Articles » PMID: 36568145

Therapeutic Drug Monitoring for Cytotoxic Anticancer Drugs: Principles and Evidence-based Practices

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Dec 26
PMID 36568145
Authors
Affiliations
Soon will be listed here.
Abstract

Cytotoxic drugs are highly efficacious and also have low therapeutic index. A great degree of caution needs to be exercised in their usage. To optimize the efficacy these drugs need to be given at maximum tolerated dose which leads to significant amount of toxicity to the patient. The fine balance between efficacy and safety is the key to the success of cytotoxic chemotherapeutics. However, it is possibly more rewarding to obtain that balance for this class drugs as the frequency of drug related toxicities are higher compared to the other therapeutic class and are potentially life threatening and may cause prolonged morbidity. Significant efforts have been invested in last three to four decades in therapeutic drug monitoring (TDM) research to understand the relationship between the drug concentration and the response achieved for therapeutic efficacy as well as drug toxicity for cytotoxic drugs. TDM evolved over this period and the evidence gathered favored its routine use for certain drugs. Since, TDM is an expensive endeavor both from economic and logistic point of view, to justify its use it is necessary to demonstrate that the implementation leads to perceivable improvement in the patient outcomes. It is indeed challenging to prove the utility of TDM in randomized controlled trials and at times may be nearly impossible to generate such data in view of the obvious findings and concern of compromising patient safety. Therefore, good quality data from well-designed observational study do add immense value to the scientific knowledge base, when they are examined in totality, despite the heterogeneity amongst them. This article compiles the summary of the evidence and the best practices for TDM for the three cytotoxic drug, busulfan, 5-FU and methotrexate. Traditional use of TDM or drug concentration data for dose modification has been witnessing a sea change and model informed precision dosing is the future of cytotoxic drug therapeutic management.

Citing Articles

Jianpi-Huatan-Huoxue-Anshen formula ameliorates gastrointestinal inflammation and microecological imbalance in chemotherapy-treated mice transplanted with H22 hepatocellular carcinoma.

Wang Y, Zhai X, Wang Z, Gao C, Mi S, Tang W World J Gastrointest Oncol. 2024; 16(10):4209-4231.

PMID: 39473963 PMC: 11514682. DOI: 10.4251/wjgo.v16.i10.4209.


Simultaneous Determination of Methotrexate Concentrations in Human Plasma and Cerebrospinal Fluid Using Two-Dimensional Liquid Chromatography: Applications in Primary Central Nervous System Lymphoma.

Wang Y, He Q, Wang F, Jiang H, Shi J, Ma J World J Oncol. 2024; 15(5):825-836.

PMID: 39328338 PMC: 11424109. DOI: 10.14740/wjon1910.


Population Pharmacokinetics in Oncology and Its Clinical Applications.

Widmer N, Guidi M, Buclin T Pharmaceutics. 2024; 16(6).

PMID: 38931835 PMC: 11207012. DOI: 10.3390/pharmaceutics16060711.


Therapeutic drug monitoring guidelines in oncology: what do we know and how to move forward? Insights from a systematic review.

Li X, Song Z, Yi Z, Qin J, Jiang D, Wang Z Ther Adv Med Oncol. 2024; 16:17588359241250130.

PMID: 38812991 PMC: 11135096. DOI: 10.1177/17588359241250130.


The Antimalarial Drug Artesunate Mediates Selective Cytotoxicity by Upregulating HO-1 in Melanoma Cells.

Jochims F, Strohm R, von Montfort C, Wenzel C, Klahm N, Kondadi A Biomedicines. 2023; 11(9).

PMID: 37760834 PMC: 10525565. DOI: 10.3390/biomedicines11092393.


References
1.
Yoshida T, Araki E, Iigo M, Fujii T, Yoshino M, Shimada Y . Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer. Cancer Chemother Pharmacol. 1990; 26(5):352-4. DOI: 10.1007/BF02897292. View

2.
Davis L, Lenkinski R, Shinkwin M, Kressel H, Daly J . The effect of dietary protein depletion on hepatic 5-fluorouracil metabolism. Cancer. 1993; 72(12):3715-22. DOI: 10.1002/1097-0142(19931215)72:12<3715::aid-cncr2820721225>3.0.co;2-w. View

3.
HILLCOAT B, McCulloch P, Figueredo A, Ehsan M, Rosenfeld J . Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion. Br J Cancer. 1978; 38(6):719-24. PMC: 2009832. DOI: 10.1038/bjc.1978.278. View

4.
Foster J, Thompson P, Bernhardt M, Margolin J, Hilsenbeck S, Jo E . A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities. Cancer Chemother Pharmacol. 2018; 83(2):349-360. DOI: 10.1007/s00280-018-3733-2. View

5.
Krivoy N, Hoffer E, Lurie Y, Bentur Y, Rowe J . Busulfan use in hematopoietic stem cell transplantation: pharmacology, dose adjustment, safety and efficacy in adults and children. Curr Drug Saf. 2008; 3(1):60-6. DOI: 10.2174/157488608783333899. View